Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

Biotechnology · market cap $38.2B · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (ADR: JHPCY) is a large-cap Chinese biotechnology company with a market capitalization of approximately $45.1 billion and a broad, diversified late-stage pipeline spanning oncology, metabolic disease, anesthesia, and rare hematologic conditions. The lead asset in the context of near-term Western catalysts is SHR-1209 (Phase 3, Primary Hypercholesterolemia), with a notable PDUFA date for Sumecigrel Capsule estimated in June 2027 representing the most impactful upcoming regulatory milestone. The pipeline encompasses more than 30 active programs across Phase 2 and Phase 3, reflecting Hengrui's scale as one of China's largest pharmaceutical innovators.

The catalyst path

2026-11-15 (est.)Phase 2 · Bupivacaine Liposome Injectionimp 7/10
2026-12-01 (est.)Phase 2 · Camrelizumab plus apatinib CohortAimp 7/10
2026-12-15 (est.)Phase 2 · HRS-5041 tabletsimp 7/10
2026-12-15 (est.)Phase 2 · SHR-3167 Injectionimp 7/10
2026-12-15 (est.)Phase 2 · SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316imp 7/10
2026-12-15 (est.)Phase 3 · Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotideimp 9/10
2026-12-31 (est.)Phase 2 · SHR-A1811imp 7/10
2026-12-31 (est.)Phase 3 · HRS-9190imp 9/10

Pipeline

Asset	Phase	Indication
Bupivacaine Liposome Injection	Phase 2	Local Analgesia Via Nerve Block
SHR-3167 Injection	Phase 2	Diabetes Mellitus, Type 2
HRS-4508+ Capecitabine	Phase 2	Solid Tumor
Retlirafusp alfa Injection	Phase 2	CRC (Colorectal Cancer)
Rocuronium	Phase 3	Neuromuscular Blockade
HRS-9190	Phase 3	Neuromuscular Blockade
HR19042 Capsules	Phase 2	IgA Nephropathy
SHR-1209	Phase 3	Primary Hypercholesterolemia
FRSW117	Phase 2	Severe Hemophilia A
HRS-4508 tablet	Phase 2	Lung Cancer
Famitinib	Phase 2	Colorectal Cancer
Pyrotinib	Phase 3	HER2-positive Breast Cancer
apatinib	Phase 3	Non-Small-Cell Lung Cancer
SHR6390	Phase 3	Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
SHR-1210	Phase 3	Nasopharyngeal Carcinoma
SHR-A1811 Injection	Phase 2	Recurrent or Metastatic Cervical Cancer
Hetrombopag Olamine	Phase 3	Severe Aplastic Anemia
SHR0302	Phase 3	Rheumatoid Arthritis
Hetrombopag	Phase 3	Chemotherapy-Induced Thrombocytopenia
HS-20093 for Injection	Phase 2	Prostate Cancer

Price & technical context

3-month

-8.1%

6-month

-25.2%

12-month

-42.6%

52-wk range

$11.50–$24.18

vs 50-day MA

-16.6%

vs 200-day MA

-23.3%

Realized vol

70.1%

Max drawdown

-52.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for JHPCY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.